Electroconvulsive Therapy: Effects, Risks, and Cognitive Impact

Electroconvulsive Therapy: Effects, Risks, and Cognitive Impact

Electroconvulsive therapy (ECT) is a medical procedure used to treat severe psychiatric disorders. While it is often utilized when other treatments fail, its application involves complex interactions with the brain and cardiovascular system. Understanding the balance between its therapeutic benefits and its potential adverse effects is critical for patients and healthcare providers.

Key Facts

  • Common side effects include confusion, memory loss, headache, nausea, and muscle soreness.
  • Cognitive impact varies; retrograde amnesia (loss of memories before treatment) is more common than anterograde amnesia.
  • Cardiac risks are a primary concern, with some updated analyses suggesting major adverse cardiac events occur in 1 in 15 to 1 in 30 patients.
  • Brain structure effects are debated, with some research indicating a decrease in gray matter volume (brain atrophy) two years post-treatment.
  • Pregnancy: ECT is generally considered relatively safe across all trimesters when specific precautions are taken.

General Adverse Effects and Immediate Risks

The general risks associated with ECT are similar to those of brief general anesthesia. According to a report by the Surgeon General of the United States, there are no absolute health contraindications for its use. However, immediately following the procedure, patients frequently experience confusion and memory loss.

Other common, transient side effects include:

  • Headache and jaw soreness
  • Nausea and vomiting
  • Fatigue and muscle soreness

To mitigate these effects, clinicians may administer low doses of benzodiazepines or general anesthetics to induce sedation without causing full unconsciousness.

Cardiovascular Risks and Mortality

The risk of death and major cardiac events is a subject of significant academic debate. Early meta-analyses suggested very low mortality rates, such as 2.1 per 100,000 procedures. However, more recent reanalyses have challenged these figures.

A 2024 reanalysis of research on Major Adverse Cardiac Events (MACE) suggests that the probability of experiencing one or more serious cardiac events—including myocardial infarction (heart attack), cardiac arrest, acute heart failure, pulmonary embolism, acute pulmonary edema, or life-threatening arrhythmia—is between 1 in 15 and 1 in 30 patients. These events are cited as a major cause of ECT-related deaths.

Patients at higher risk include those with:

  • Unstable or severe cardiovascular conditions or aneurysms
  • Recent history of stroke
  • Increased intracranial pressure (e.g., from a brain tumor)
  • Severe pulmonary conditions

Cognitive Impairment and Memory Loss

Cognitive impairment is one of the most discussed side effects of ECT. The American Psychiatric Association (APA) has acknowledged that some patients may experience persistent or permanent memory loss.

Types of Amnesia

ECT can cause two types of amnesia: retrograde amnesia (loss of memories for events occurring before treatment) and anterograde amnesia (loss of memories for events occurring after treatment). Anterograde loss typically resolves within 2 to 4 weeks, while retrograde amnesia—which primarily affects autobiographical rather than semantic memory—can take weeks or months to resolve, though it rarely persists beyond one year.

Factors Increasing Cognitive Risk

Certain treatment parameters are associated with more intense cognitive side effects:

  • Bilateral electrode placement (compared to unilateral)
  • Sine wave stimulation (compared to brief-pulse currents)
  • Higher electrical dosages relative to the seizure threshold
  • A larger number of treatments or closely spaced sessions
  • Concurrent use of psychotropic medications or high-dose barbiturate anesthetics

Impact on Brain Structure and Function

There is ongoing controversy regarding whether ECT causes structural brain damage. While some mental health associations and the US Surgeon General have stated there is no evidence of gross structural pathology, other findings suggest functional and structural changes.

High-resolution magnetoencephalography (MEG) imaging has shown an increase in loudness dependence of auditory evoked potentials (LDAEP), meaning patients may become disproportionately sensitive to sound. Additionally, ECT increases "aperiodic activity," which can impair the brain's ability to coordinate balance and filter unnecessary sensory input.

Long-term structural studies indicate that while some brain structures may appear enlarged immediately after ECT, they may be significantly reduced in size two years later, falling below pre-treatment levels. This reduction in gray matter volume is a primary indicator of brain atrophy.

Summary of ECT Effects

Summary of ECT Adverse Effects and Risks
Category Common/Low-Risk Effects Severe/High-Risk Effects
Physical Headache, nausea, muscle soreness Major Adverse Cardiac Events (MACE)
Cognitive Transient confusion, short-term memory loss Persistent retrograde amnesia, brain atrophy
Neurological Increased sound sensitivity (LDAEP) Intraparenchymal hemorrhage (extremely rare)

Special Considerations: Adolescents and Pregnancy

In adolescents (ages 12–17), ECT is considered highly efficient for several psychiatric disorders with relatively benign side effects, though some studies note a high prevalence of "acceptable" memory loss.

For pregnant women, ECT is generally considered safer than many pharmacological alternatives across all trimesters. To minimize risk, recommended precautions include:

  • Pelvic examinations and uterine tocodynamometry
  • Intravenous hydration and nonparticulate antacids
  • Elevation of the right hip during the procedure
  • External fetal cardiac monitoring and intubation

Frequently Asked Questions

Does ECT cause permanent memory loss?

While most memory loss is transient, the American Psychiatric Association recognizes that in some cases, recovery from retrograde amnesia may be incomplete, resulting in persistent or permanent memory loss.

What are the cardiac risks associated with ECT?

ECT can cause heart arrhythmia, lack of blood flow/oxygen to the heart, and persistent asystole. Recent reanalyses suggest a significant risk of major adverse cardiac events in between 1 in 15 and 1 in 30 patients.

Is ECT safe during pregnancy?

Yes, it is generally considered relatively safe during all trimesters, provided that specific technical modifications and monitoring (such as fetal cardiac monitoring and hip elevation) are implemented.

What is the difference between bilateral and unilateral ECT regarding memory?

Bilateral electrode placement is generally associated with more pronounced memory loss and confusion compared to unilateral placement, although it may be more efficacious for certain mood disorders.

Can ECT lead to brain atrophy?

Some evidence suggests that two years after treatment, there is a significant decrease in gray matter volume compared to pre-treatment levels, which is an indicator of brain atrophy.

References

  1. Bakalar N (September 14, 2021). "ECT Can Be a Good Treatment Option for Serious Depression". The New York Times.
  2. Rudorfer MV, Henry ME, Sackeim HA (2003). "Electroconvulsive therapy" (PDF). In Tasman A, Kay J, Lieberman JA (eds.). Psychiatry (Second ed.). Chichester: John Wiley & Sons Ltd. pp. 1865–1901. Archived (PDF) from the original on 2007-08-10.
  3. FDA. FDA Executive Summary. Prepared for the January 27–28, 2011 meeting of the Neurological Devices Panel Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT). Quote, p. 38: "Three major practice guidelines have been published on ECT. These guidelines include: APA Task Force on ECT (2001); Third report of the Royal College of Psychiatrists' Special Committee on ECT (2004); National Institute for Health and Clinical Excellence (NICE 2003; NICE 2009). There is significant agreement between the three sets of recommendations."
  4. "- Reports of the Surgeon General - Profiles in Science Search Results". profiles.nlm.nih.gov. Retrieved 2025-04-10.
  5. American Psychiatric Association, Committee on Electroconvulsive Therapy, Richard D. Weiner (chairperson), et al. (2001). The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging (2nd ed.). Washington, DC: American Psychiatric Publishing. ISBN 978-0-89042-206-9.